Telix Pharmaceuticals: Submits clinical briefing package to U.S. FDA

Telix Pharmaceuticals: Submits clinical briefing package to U.S FDA

• Telix Pharmaceuticals has submitted a clinical briefing package to the U.S FDA for its prostate cancer treating drug
• This comes after procedural guidance received from its pre-NDA meeting
• The company has also completed the additional manufacturing and product release analytics that recommended by the FDA
• Then the new drug targets cell surface prostate-specific antigen that over-expressed on most prostate cancer cells
• Current treatments also include palliative care, radiation therapy, prostatectomy and chemotherapy
• Telix is currently down a 2.80 per cent with shares trading for $1.57 apiece